SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending with community chatter focusing on the stock's recent upward momentum, driven by speculation around potential catalysts and technical factors. Some traders point to a possible gamma squeeze and overall market strength, while others express skepticism, citing valuation concerns and mixed fundamentals. The discussion includes debate on whether the rally is sustainable or if a pullback is imminent.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is experiencing a surge in community interest, potentially fueled by a recent tweet and anticipation of a "God candle." Discussions revolve around the stock's squeezability, the promise of future technologies, and the belief in nodules as a source of power. Some investors are closely monitoring technical indicators, while others await a headline catalyst.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

GEMI is trending following its IPO, with the community actively discussing allocation strategies and potential volatility. Initial trading saw a halt, sparking debates about market manipulation and comparisons to other hyped IPOs. Bullish sentiment remains as traders speculate on the stock's potential, while others express concern over its balance sheet.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

aTyr Pharma (ATYR) is trending amid anticipation for Phase 3 trial results, expected mid-September, with the community debating potential outcomes and impact on the company's pipeline. Discussions revolve around short squeeze potential, institutional ownership, and comparisons to other biotech firms facing binary events. Some traders are focused on options activity and hedging strategies, while others scrutinize analysts' price targets and historical accuracy.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid heated debates and political polarization following a shooting involving Charlie Kirk, with community members clashing over the shooter's motives and affiliations. Discussions involve broader issues of gun control, political extremism, and the release of the Epstein files. The community is also focused on the company's financial prospects and ties to Donald Trump.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FCEL is trending due to recent earnings and increased discussion around its potential in AI data center power, with community members highlighting its fast “contract-to-power” deployment. Some are expressing optimism for a continued rally, while others are debating the company's path to profitability and comparing it to sector peers like BE and PLUG. Discussion also includes potential catalysts such as new deals, partnerships, and broader adoption of clean energy initiatives.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending following news that its Black Widow drone system has been approved for NATO procurement, potentially opening up significant sales opportunities. Community members are actively discussing the implications of this approval, particularly its long-term impact and revenue potential, while also debating the stock's valuation compared to sector peers. Bullish sentiment revolves around the expectation of increased revenues and potential contracts stemming from NATO countries.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to regulatory clearance for its acquisition of Oxford Ionics, sparking discussions about the company's future and potential catalysts such as the upcoming Quantum World Congress. Community perspectives are mixed, with some highlighting the acquisition's significance while others express concerns about revenue and valuation. The stock is also being compared to NVDA, with some seeing it as the next big thing in computing.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recently announced $20 million investment agreement, sparking significant volatility and a mixed sentiment among traders. The community is actively discussing the potential for a short squeeze and upcoming news related to a conference. Some traders express concerns about dilution and the stock's history, while others remain optimistic about its long-term potential, especially with news expected next week.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer ($PFE) is trending due to reports suggesting the Trump administration may link COVID-19 vaccines to child deaths, sparking concerns about potential liabilities and renewed scrutiny of vaccine safety data. The community is debating the validity of the reports and the potential impact on vaccine manufacturers, while some investors see the dip as a buying opportunity for the high-dividend stock.  Others believe Pfizer is more than just a vaccine company and should be evaluated as a cancer treatment company.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet

The consensus price target hints at a 142.7% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of +22.47% and -26.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

Shares of uniQure N.V. (QURE) were in the spotlight on Friday morning after its first quarter (Q1) revenue fell 81% year-on-year (YoY) while losses narrowed.The gene therapy company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/09/3078125/0/en/uniQure-Announces-First-Quarter-2025-Financial-Results-and-Highlights-of-Recent-Company-Progress.html">reported</a> revenue for the three months ended March of $1.6 million, compared to $8.5 million in the same period of 2024, and below an analyst estimate of $6.71 million, as per Finchat data.The company attributed the revenue fall to a decrease of $4 million in contract manufacturing of HEMGENIX gene therapy for biotherapeutics company CSL Behring, among other factors.uniQure, however, narrowed its quarterly loss to $0.82 per share, compared to a loss of $1.36 in the corresponding period of 2024. Analysts were estimating a loss of $1.06 per share.The narrowing of the net loss in the quarter was driven by a significant reduction in the company’s operating expenses, as it slashed employee-related expenses, facility expenses, and costs related to preclinical supplies.The firm ended the quarter with cash, cash equivalents, and current investment securities of approximately $409 million, expected to fund its operations into the second half of 2027.The company is now seeking U.S. FDA approval for its AMT-130 gene therapy as a treatment for Huntington’s disease.CEO Matt Kapusta said that the company expects to provide a regulatory update on AMT-130 in the second quarter, including guidance on the potential timing for its application to the FDA seeking approval to distribute the therapy.On Stocktwits, retail sentiment around uniQure remained unmoved within the ‘neutral’ territory over the past 24 hours while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_09_at_8_08_00_AM_png_281dbf2952.webp" alt="QURE's Sentiment Meter and Message Volume as of 8:08 a.m. ET on May 9, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>QURE's Sentiment Meter and Message Volume as of 8:08 a.m. ET on May 9, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/QURE/sentiment">QURE stock</a> declined by 32% this year but is up by about 142% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-reports-positive-data-from-cancer-drug-trial/chiWpd3RblJ">AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode

The company narrowed its first-quarter loss to $0.82 per share, down from $1.36 per share in 2024. 

Equity

Biotech stocks jump as Makary outlines FDA vision, RBC comments

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

Shares of gene therapy developer uniQure N.V. (QURE) shot up 41% on Thursday afternoon after it <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.uniqure.com/investors-media/press-releases">announced</a> that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to its AMT-130 gene therapy for the treatment of Huntington’s disease.The new designation is in addition to the existing Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track designations granted to AMT-130.uniQure CEO Walid Abi-Saab said that the designation underscores both the urgent need for effective treatments for Huntington’s disease and the encouraging interim data demonstrating that AMT-130 has the potential to slow disease progression.He added that the company looks to commercialize the drug as quickly as possible.Forty-five patients have received AMT-130 to date as part of trials, the company stated, while adding that an additional regulatory update regarding its Biologics License Application submission to the FDA requesting marketing approval is expected in the second quarter.Huntington’s disease is a rare, inherited neurodegenerative disorder. According to a 2021 study in Neuroepidemiology, approximately 70,000 people have been diagnosed with Huntington’s disease in the U.S. and Europe, with hundreds of thousands of others at risk of inheriting it.FDA’s Breakthrough Therapy designation is intended to expedite the development and review of investigational therapeutic candidates that are intended to treat a serious condition, and if preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy.On Stocktwits, retail sentiment around uniQure flipped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘low’ to ‘extremely high’.<figure class="image"><img style="aspect-ratio:1292/302;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_17_at_12_38_37_PM_png_86c013b014.webp" alt="QURE's Sentiment Meter and Message Volume as of 12:40 p.m. ET on April 17, 2025 | Source: Stocktwits" width="1292" height="302"><figcaption>QURE's Sentiment Meter and Message Volume as of 12:40 p.m. ET on April 17, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is down approximately 27% year-to-date but up about 183% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/spirit-airlines-appoints-dave-davis-as-ceo/chQEDnoRbfA">Spirit Airlines Appoints Dave Davis As CEO After Emerging From Bankruptcy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic

The new designation is in addition to the existing Regenerative Medicine Advanced Therapy, Orphan Drug, and Fast Track designations granted to AMT-130.

CSL Behring's Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

CSL Behring's Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B CSL Behring's Gene...

Shares of gene therapy company uniQure more than doubled on Tuesday before trimming some gains, reaching their highest levels since mid-June 2023.The surge came after uniQure announced it had reached an agreement with the U.S. Food and Drug Administration (FDA) on key aspects of an Accelerated Approval pathway for its AMT-130 treatment, a potential therapy for Huntington’s disease.&nbsp;This agreement means data from the ongoing Phase I/II studies, compared to an external control, could serve as the primary basis for a biologics license application (BLA) submission without requiring an additional pre-submission study.uniQure’s AMT-130 previously received a regenerative medicine advanced therapy (RMAT) designation from the FDA in May, underscoring its potential to address unmet medical needs in Huntington’s disease.&nbsp;Analysts have viewed this development as a major milestone.Cantor Fitzgerald analyst Kristen Kluska raised her price target for uniQure to $58 from $28 and maintained an ‘Overweight’ rating, noting that the FDA’s approval signals potential pharma interest given the clearer path toward market entry.Stifel also weighed in, describing the development as “a best-case scenario” and noting that uniQure can use external controls and data from ongoing studies.&nbsp;Stifel has a ‘Buy’ rating and predicts the FDA agreement will bolster confidence in uniQure’s pipeline, despite the low initial expectations for this accelerated pathway.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/QURE_sentiment_and_message_volume_Dec_10_premarket_98c55fcc19.png" alt="QURE sentiment and message volume Dec 10 premarket.png" width="1318" height="324"><figcaption>QURE sentiment and message volume Dec 10 premarket as of 11:45 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned ‘extremely bullish’, with QURE trending among the top 10 tickers late Tuesday morning.<stembedurl>https://stocktwits.com/nbkihy8/message/595867060</stembedurl><stembedurl>https://stocktwits.com/DaBeavzz65/message/578931944</stembedurl>uniQure’s stock has more than doubled in value this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Neurons in dementia, conceptual illustration - stock illustration

uniQure Stock Hits 18-Month High After FDA Agreement Clears Pathway For Huntington’s Treatment: Retail Gets More Optimistic

uniQure’s AMT-130 previously received a regenerative medicine advanced therapy designation from the FDA in May.

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA PR...

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

QURE
uniQure N.V.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest QURE News

QURE uniQure N.V.